Evaluation of PIK3CA Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer.
Journal of Clinical Oncology – December 2013
![](https://ingenox.com/wp-content/plugins/bb-plugin/img/pixel.png)
Evaluation of PIK3CA Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer
December 10, 2013